On May 3, before market open, CGI Group will report its Q2, 2017 results. Tse thinks the company will generate operating EPS of $0.90 on revenue of $2.6-billion.
While CGI’s stock has been flat for much of the year, the analyst thinks there is reason to believe that might not continue, and that some upside surprises may develop.
“Bottom line, we think the lack of newsflow and in particular a subtle tone on acquisitions has had the stock languishing this year when it comes to performance against some of the notable comps, in particular the European-focused names like Atos and Capgemini,” says Tse. “That said, we don’t believe that’s changed the strategy at all; we continue to believe CGI continues to actively evaluate acquisitions but unlike year’s past, we think an added growth drive continues to come on stream in the form of organic growth that’s led by IP-focused solutions. For that reason, we believe there’s a relative opportunity in GIB.a / GIB today.”
In a research update to clients today, Tse maintained his “Outperform” rating and one-year price target of (C) $80.00 on CGI Group, implying a return of 26 per cent at the time of publication.
Tse thinks CGI Group will generate EBITDA of $1.98-billion on revenue of $10.69-billion in fiscal 2017. He expects these numbers will improve to EBITDA of $2.09-billion on a topline of $11.22-billion the following year.
National Bank Financial analyst Richard Tse said the impact of AI on tech valuations is becoming more company-specific, with names… [Read More]
ScotiaMcLeod Newman Group advisor and portfolio manager Greg Newman told BNN Bloomberg’s Market Call on April 24 that Meta Platforms … [Read More]
Goodreid Investment Counsel president and CEO Gordon Reid told BNN Bloomberg’s Market Call on April 23 that McKesson (McKesson Stock… [Read More]
Beacon Securities analyst Russell Stanley initiated coverage of Metatek-Group (Metatek-Group Stock Quote, Chart, News, Analysts, Financials TSX:MTEK) with a “Buy”… [Read More]
Clarus Securities analyst Noel Atkinson said in an April 23 update that AmeriTrust Financial Technologies (AmeriTrust Financial Technologies Stock Quote,… [Read More]
Haywood analyst Neal Gilmer said the U.S. decision to immediately reclassify state-licensed medical marijuana from Schedule I to Schedule III… [Read More]